China has put appointments, consultations and even AI doctor avatars inside WeChat and Alipay, while its drug pipeline is being bought up by Western pharma.
In China, the first step to seeing a doctor is opening your phone. You book a hospital slot through WeChat or Alipay, consult a doctor on a telemedicine platform, or chat with an AI doctor avatar about anything from insomnia to diabetes.
The government has pushed digital health forward so that all 1.4 billion people can get care. The urban-rural gap and a thin primary care network are the old problems it is trying to solve.
In the West, tech is a screw on a rusty machine
Ruby Wang, a physician and health tech consultant, writes about this in her book China Cure. In the UK and the US, she says, tech is always an add-on to the health system — an extra screw turned into a rusty machine.
In China the digital rails are already there, and society treats that as normal. With so many people, convenience and access have to come first, because there is no other way.
She notes this is not unique to China. Brazil, Kenya and Ethiopia look similar. A country developing frantically does not have the luxury of waiting and watching.
Her caveat: China's digital health is not directly exportable. The West would never accept an AI doctor avatar.
Pfizer is queuing up for Chinese drugs
The harder part is medicine. More clinical trials now run in China than in the US, and China accounts for half of global drug licensing deals. This year the share could reach 60%.
It took decades of tuition: tax incentives, office space, capital, waiting for talent to come home. That built scale, and with so many patients, no disease counts as rare.
Weak spots remain. China is strongest in oncology, less mature in immunology. Chinese firms know how to build a drug, not how to sell it, which is why they license it to Pfizer and let Pfizer sell it in America.
The US is debating whether to use Chinese drugs at all. Bills like the Biosecure Act aim to block them. Wang's counter: under WTO rules, medicines should not be subject to tariffs, because access to them is a human right.
The argument that works, she says, is that American companies will make money too.
Why it matters
Moving the whole doctor's visit onto a phone means 1.4 billion people can actually get an appointment — but who holds the data and algorithms underneath is a question almost nobody asks. Cheap, scalable Chinese health products are a real opening for developing countries, and the reasons for blocking them are rarely written on the bottle.
Curated from high-quality sources, with concise summaries and key takeaways.
